Initiated Buy X

ASND Ascendis Pharma

UBS

$196

Upgrades Perform Outperform X

ASND Ascendis Pharma

Oppenheimer

$180

Upgrades Hold Buy X

ASND Ascendis Pharma

TD Cowen

$156 $175

Initiated Buy X

ASND Ascendis Pharma

Stifel

$200

Resumed Neutral X

ASND Ascendis Pharma

Credit Suisse

$89

Downgrades Outperform Perform X

ASND Ascendis Pharma

Oppenheimer

Downgrades Overweight Eq-Weight X

ASND Ascendis Pharma

Morgan Stanley

$151 $108

Downgrades Outperform Neutral X

ASND Ascendis Pharma

Credit Suisse

Initiated Buy X

ASND Ascendis Pharma

Goldman

$174

Resumed Buy X

ASND Ascendis Pharma

Berenberg

$166

Resumed Outperform X

ASND Ascendis Pharma

Wedbush

$163

Upgrades Neutral Buy X

ASND Ascendis Pharma

BofA Securities

$148 $161

Initiated Market Perform X

ASND Ascendis Pharma

Cowen

$136

Initiated Overweight X

ASND Ascendis Pharma

Wells Fargo

$176

Downgrades Buy Neutral X

ASND Ascendis Pharma

BofA Securities

$164 $169

Downgrades Outperform Perform X

ASND Ascendis Pharma

Oppenheimer

Resumed Buy X

ASND Ascendis Pharma

Stifel

$190

Initiated Outperform X

ASND Ascendis Pharma

Evercore ISI

Initiated Overweight X

ASND Ascendis Pharma

Cantor Fitzgerald

$102

Upgrades Mkt Perform Outperform X

ASND Ascendis Pharma

Leerink Partners

Initiated Buy X

ASND Ascendis Pharma

Stifel

$85

Reiterated Mkt Perform X

ASND Ascendis Pharma

Leerink Partners

$37 $64

ASND  Ascendis Pharma A/S - ADS

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.